COGNITION THERAPEUTICS, INC.
Cognition Therapeutics, Inc. (CGTX) is a clinical‑stage biotechnology company developing treatments for neurodegenerative diseases, notably Alzheimer’s. Its lead programme targets toxic oligomer interactions believed to drive neuronal damage, with clinical data and regulatory developments acting as key catalysts. With a market capitalisation around $156.2 million, Cognition is a small‑cap, high‑volatility stock that depends on successful trial results, partnerships and timely financing. That profile can offer upside if programmes advance, but also carries substantial clinical, regulatory and funding risk — including potential dilution. Investors should monitor clinical readouts, cash runway, peer developments and intellectual property position. This is general educational information, not personal financial advice; outcomes are uncertain and losses are possible. Consider your risk tolerance and diversification when evaluating speculative biotech investments.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Cognition Therapeutics' stock with a target price of $6.13, indicating strong potential for growth.
Financial Health
Cognition Therapeutics is showing positive cash flow and solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CGTX
Early Alzheimer's Detection: Could Blood Tests Replace Scans?
The FDA's approval of Roche and Eli Lilly's blood test marks a pivotal shift toward early and accessible Alzheimer's diagnosis in primary care. This breakthrough is expected to accelerate growth for companies in the diagnostics sector and expand the market for new Alzheimer's treatments.
Published: October 14, 2025
Explore BasketPharma's Renewed Focus On Mental Health
AbbVie's potential $1 billion acquisition of Gilgamesh Pharmaceuticals signals a major strategic investment in the mental health sector. This move is expected to increase M&A interest and valuations for other biotech firms developing innovative psychiatric therapies.
Published: July 31, 2025
Explore BasketBeyond Leqembi: The Alzheimer's Treatment Frontier
New long-term data shows Eisai and Biogen's Alzheimer's drug, Leqembi, effectively slows cognitive decline over four years, confirming its market-leading position. This breakthrough validates the underlying scientific approach, creating investment opportunities in other companies developing similar neurodegenerative therapies and diagnostic tools.
Published: July 30, 2025
Explore BasketThe Alzheimer's Treatment Ecosystem
Following the EU regulator's approval of Eli Lilly's Alzheimer's drug, Kisunla, a new investment opportunity has emerged. This theme focuses on companies that provide essential support services, such as genetic testing and advanced imaging, which are crucial for the drug's administration and monitoring.
Published: July 27, 2025
Explore BasketSafer Alzheimer's Treatments
This carefully selected group of stocks represents companies at the forefront of developing safer, more effective Alzheimer's treatments. The FDA's recent approval of improved dosing for breakthrough therapies has created significant new opportunities in this rapidly evolving field.
Published: July 11, 2025
Explore BasketBrain-Computer Interface
This collection features pioneering companies creating revolutionary pathways between the human brain and machines. These carefully selected stocks represent the cutting edge of neural technology, with potential to transform healthcare and computing through innovative brain signal interpretation.
Published: June 17, 2025
Explore BasketBio-Hacking Portfolio
Discover companies at the cutting edge of human optimization, where biology meets technology. These carefully selected stocks represent innovators developing data-driven solutions for personalized health, enhanced performance, and extended longevity.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Readouts Ahead
Upcoming trial results can reshape prospects and investor sentiment, though clinical failure remains a common outcome.
Science Focus
Programmes target toxic protein interactions in neurodegeneration — scientifically interesting but reliant on clinical validation.
Small‑Cap Dynamics
Market cap around $156M means liquidity and financing are important; share prices can move sharply and dilution is possible.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
